Neuralink’s Billion-Dollar Blueprint by 2031
Neuralink, the brain-chip company founded by Elon Musk, is aiming to generate $1 billion in annual revenue by 2031 through brain implant surgeries for 20,000 individuals each year, according to a report by Bloomberg News, cited by Reuters.
The company plans to launch five major clinics within the next six years and introduce three flagship brain-implant products: Telepathy (enabling communication between the brain and external devices), Blindsight (to restore vision), and Deep (targeting conditions like tremors and Parkinson’s disease).
Neuralink expects to secure approval from the U.S. Food and Drug Administration (FDA) for its Telepathy device by 2029. At that point, it hopes to perform around 2,000 surgeries annually, generating approximately $100 million in revenue. By 2030, the company aims to roll out Blindsight, increase annual surgeries to 10,000, and earn over half a billion dollars in revenue.
Founded in 2016, Neuralink has raised nearly $1.3 billion in funding to date and is currently valued at around $9 billion.
The company began human trials of its experimental brain chip in 2024. As of now, five patients with severe paralysis are reportedly able to control digital and real-world devices using only their thoughts.
